Published in J Clin Invest on June 01, 2004
Epidermal barrier formation and recovery in skin disorders. J Clin Invest (2006) 4.14
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med (2005) 4.04
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med (2006) 3.38
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet (2007) 2.78
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A (2005) 2.47
CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest (2009) 1.65
Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest (2006) 1.58
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol (2009) 1.49
Corticotropin releasing hormone and the skin. Front Biosci (2006) 1.45
Community differentiation of the cutaneous microbiota in psoriasis. Microbiome (2013) 1.44
Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan. PLoS One (2016) 1.40
CXCR2 ligands and G-CSF mediate PKCalpha-induced intraepidermal inflammation. J Clin Invest (2006) 1.36
Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol (2008) 1.31
Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: a hospital-based case-control study. Indian J Dermatol (2012) 1.28
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest (2008) 1.27
Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. Am J Pathol (2006) 1.24
Epigenetics in human autoimmunity. Epigenetics in autoimmunity - DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity (2008) 1.23
Connexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response. J Clin Invest (2006) 1.22
Impaired Langerhans cell migration in psoriasis. J Exp Med (2006) 1.16
Role of LIM kinases in normal and psoriatic human epidermis. Mol Biol Cell (2006) 1.14
The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol (2012) 1.08
Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS One (2013) 1.07
Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci (2010) 1.06
Psoriasis and its management. BMJ (2006) 1.05
Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol (2007) 1.04
The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res (2006) 1.03
Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. J Med Genet (2005) 1.03
Interleukin-1 regulates keratinocyte expression of T cell targeting chemokines through interleukin-1 receptor associated kinase-1 (IRAK1) dependent and independent pathways. Cell Signal (2009) 1.00
Cytokines in psoriasis. Cytokine (2015) 0.98
Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs. Expert Opin Drug Deliv (2010) 0.98
Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice. Proc Natl Acad Sci U S A (2014) 0.92
The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res (2006) 0.90
Epidermal Differentiation in Barrier Maintenance and Wound Healing. Adv Wound Care (New Rochelle) (2014) 0.90
Protecting the boundary: the sentinel role of host defense peptides in the skin. Cell Mol Life Sci (2011) 0.89
Antipsoriatic effects of avarol-3'-thiosalicylate are mediated by inhibition of TNF-alpha generation and NF-kappaB activation in mouse skin. Br J Pharmacol (2007) 0.89
Psoriasis and uveitis: a literature review. An Bras Dermatol (2012) 0.88
CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets (2010) 0.88
Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21. Hum Genet (2005) 0.88
Recombinant integrin CD11b A-domain blocks polymorphonuclear cells recruitment and protects against skeletal muscle inflammatory injury in the rat. Immunology (2006) 0.87
Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian J Dermatol (2011) 0.86
The circadian clock in skin: implications for adult stem cells, tissue regeneration, cancer, aging, and immunity. J Biol Rhythms (2015) 0.85
The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res (2007) 0.84
Associations between tumor necrosis factor-α polymorphisms and risk of psoriasis: a meta-analysis. PLoS One (2013) 0.84
New ENU-induced semidominant mutation, Ali18, causes inflammatory arthritis, dermatitis, and osteoporosis in the mouse. Mamm Genome (2006) 0.84
Screening of flavonoid "quercetin" from the rhizome of Smilax china Linn. for anti-psoriatic activity. Asian Pac J Trop Biomed (2012) 0.83
Metabolic syndrome and skin: psoriasis and beyond. Indian J Dermatol (2013) 0.83
The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice. EMBO J (2009) 0.83
Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. Eur J Dermatol (2009) 0.83
Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer. J Biomed Biotechnol (2012) 0.82
Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res (2007) 0.82
Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. Dermatol Ther (Heidelb) (2012) 0.81
Influence of ustekinumab on body weight of patients with psoriasis: an initial report. Postepy Dermatol Alergol (2014) 0.81
Pattern VEP alterations in psoriatic patients may indicate a sub clinic optic neuritis. Doc Ophthalmol (2005) 0.81
Infliximab for the treatment of plaque psoriasis. Biologics (2008) 0.79
Immunobiologics in the treatment of psoriasis. Clin Immunol (2007) 0.79
Psoralen-ultraviolet A treatment with Psoralen-ultraviolet B therapy in the treatment of psoriasis. Pak J Med Sci (2013) 0.78
Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci (2007) 0.78
Fulminant ulcerative colitis associated with steroid-resistant minimal change disease and psoriasis: a case report. World J Gastroenterol (2007) 0.77
IL-10 implications in psoriasis. Int J Health Sci (Qassim) (2008) 0.77
Inhibition of imiquimod-induced psoriasis-like dermatitis in mice by herbal extracts from some Indian medicinal plants. Protoplasma (2015) 0.77
Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. Int J Nanomedicine (2017) 0.76
Decreased Expression of Caveolin-1 Contributes to the Pathogenesis of Psoriasiform Dermatitis in Mice. J Invest Dermatol (2015) 0.76
Synovial tissue response to treatment in psoriatic arthritis. Open Rheumatol J (2011) 0.76
The differential regulation of human ACT1 isoforms by Hsp90 in IL-17 signaling. J Immunol (2014) 0.76
Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician (2012) 0.76
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. BMC Dermatol (2006) 0.76
Ethnopharmacological survey of medicinal plants used by patients with psoriasis in the West Bank of Palestine. BMC Complement Altern Med (2017) 0.76
Study on Certain Biomarkers of Inflammation in Psoriasis Through "OMICS" Platforms. Open Biochem J (2014) 0.76
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol (2016) 0.75
Disease Severity, Quality of Life, and Psychiatric Morbidity in Patients With Psoriasis With Reference to Sociodemographic, Lifestyle, and Clinical Variables: A Prospective, Cross-Sectional Study From Lahore, Pakistan. Prim Care Companion CNS Disord (2015) 0.75
G-231A and G+70C Polymorphisms of Endothelin Receptor Type-A Gene could Affect the Psoriasis Area and Severity Index Score and Endothelin 1 Levels. Indian J Dermatol (2015) 0.75
Genetic background of psoriasis. Int J Health Sci (Qassim) (2010) 0.75
Antipsoriatic activity of ethanolic extract of Woodfordia fruticosa (L.) Kurz flowers in a novel in vivo screening model. Indian J Pharmacol (2016) 0.75
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol (2011) 0.75
Influence of Psoriasis on Household Chores and Time Spent on Skin Care at Home: A Questionnaire Study. Dermatol Ther (Heidelb) (2015) 0.75
Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab. Patient Prefer Adherence (2014) 0.75
Association of Angiotensin-Converting Enzyme (ACE) Gene Polymorphism with Inflammation and Cellular Cytotoxicity in Vitiligo Patients. PLoS One (2015) 0.75
Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center. J Transl Med (2016) 0.75
Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. PLoS One (2015) 0.75
Evaluation of psoriasis patients' attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments. Patient Prefer Adherence (2017) 0.75
Inositoylated platelet-activating factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models. J Invest Dermatol (2014) 0.75
[A decade of biologics in dermatology]. Hautarzt (2012) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem (2002) 14.34
The danger model: a renewed sense of self. Science (2002) 13.85
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet (2001) 11.12
Points of control in inflammation. Nature (2002) 10.61
Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol (2002) 10.15
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 6.49
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67
An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet (2003) 4.61
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov (2003) 4.58
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
The immunological synapse. Annu Rev Immunol (2001) 4.45
Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature (2003) 4.22
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet (2002) 4.03
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
Disease concomitance in psoriasis. J Am Acad Dermatol (1995) 3.92
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol (2001) 3.92
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med (2001) 3.69
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science (2003) 3.19
The pathophysiology of psoriasis. Lancet (1991) 2.99
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol (2003) 2.91
Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol (1985) 2.74
Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology (2003) 2.72
Dermal injection of immunocytes induces psoriasis. J Clin Invest (1996) 2.64
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med (2004) 2.63
Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet (1997) 2.48
Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell (2001) 2.45
Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet (1997) 2.43
Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol (1991) 2.24
Signaling life and death in the thymus: timing is everything. Science (2003) 2.20
The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol (2002) 2.15
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet (2001) 2.11
Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today (1995) 2.09
Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med (1995) 2.09
The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol (1993) 2.04
Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science (1994) 1.99
The natural history of psoriasis in 5,600 patients. Dermatologica (1974) 1.98
Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol (2002) 1.95
The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet (1998) 1.94
Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med (2003) 1.90
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med (2002) 1.86
The cytokine network in psoriasis. Arch Dermatol (1991) 1.85
Psoriasis and HLA-Cw6. Br J Dermatol (1980) 1.83
Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med (2002) 1.75
Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol (2000) 1.73
Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol (1994) 1.72
Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest (1994) 1.71
T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol (1994) 1.62
Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest (2000) 1.60
Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol (1999) 1.57
Persistence of T-cell clones in psoriatic lesions. Arch Dermatol (1997) 1.52
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 1.48
Cutting edge: negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly. J Immunol (2002) 1.44
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest (1998) 1.40
CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet (2003) 1.38
Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest (2003) 1.37
Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol (2000) 1.37
Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J (2001) 1.34
Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther (1999) 1.31
Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol (2000) 1.29
Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest (2004) 1.28
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet (2002) 1.24
Pulling the trigger on psoriasis. Nature (1996) 1.24
Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest (1999) 1.21
Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science (1985) 1.18
Immunologic mechanisms in psoriasis. J Am Acad Dermatol (1988) 1.15
Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci (2000) 1.15
Skin innate immune system in psoriasis: friend or foe? J Clin Invest (1999) 1.14
Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint. J Cutan Pathol (2001) 1.13
Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics (2002) 1.12
Searching for the major histocompatibility complex psoriasis susceptibility gene. J Invest Dermatol (2002) 1.12
A RUNX trio with a taste for autoimmunity. Nat Genet (2003) 1.07
Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol (2002) 1.06
The immunologic and genetic basis of psoriasis. Arch Dermatol (1999) 1.05
CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J Immunol (2003) 1.03
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest (2002) 1.02
Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol (2002) 1.02
The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am J Hum Genet (2003) 1.01
Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med (2003) 1.00
Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol (2003) 0.99
Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol (2000) 0.97
Psoriasis. J Am Acad Dermatol (1984) 0.97
Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol (2002) 0.95
Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol (2001) 0.95
Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol (2001) 0.93
Expression of IL-18 in psoriasis. Arch Dermatol Res (2001) 0.93
Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol (2002) 0.91
Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J Clin Invest (1999) 0.91
Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol (1989) 0.91
Activated keratinocytes present bacterial-derived superantigens to T lymphocytes: relevance to psoriasis. J Dermatol Sci (1993) 0.89
Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br J Dermatol (1999) 0.87
The endothelium in psoriasis. Br J Dermatol (1995) 0.86
Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol (2002) 0.86
Reactivity of resident immunocytes in normal and prepsoriatic skin using an ex vivo skin-explant model system. Arch Pathol Lab Med (2003) 0.86
Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther (2003) 0.85
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet (2012) 6.97
The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet (2011) 5.95
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 3.93
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet (2007) 2.78
Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med (2007) 2.70
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med (2004) 2.63
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 2.46
Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet (2008) 2.42
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet (2011) 2.21
Psoriasis. Annu Rev Pathol (2011) 2.21
Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res (2002) 2.06
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96
Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med (2012) 1.81
Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol (2011) 1.79
The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One (2011) 1.71
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol (2010) 1.61
Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med (2011) 1.56
Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol (2007) 1.46
The multitasking organ: recent insights into skin immune function. Immunity (2011) 1.38
Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med (2003) 1.34
Gene expression changes with age in skin, adipose tissue, blood and brain. Genome Biol (2013) 1.34
The cytokine and chemokine network in psoriasis. Clin Dermatol (2007) 1.31
Unraveling the autoimmune translational research process layer by layer. Nat Med (2012) 1.27
The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol (2007) 1.27
TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol (2013) 1.20
Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol (2004) 1.16
IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest (2013) 1.12
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol (2007) 1.10
A systems model for immune cell interactions unravels the mechanism of inflammation in human skin. PLoS Comput Biol (2010) 1.07
Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Hum Mol Genet (2012) 1.06
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood (2003) 1.05
Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype. PLoS One (2012) 1.04
Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother (2011) 1.03
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother (2008) 0.99
A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol (2008) 0.99
Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood (2003) 0.96
Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis (2013) 0.95
The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol (2013) 0.95
High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother (2003) 0.94
Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood (2002) 0.93
The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep (2010) 0.92
Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One (2011) 0.92
Integration of lyoplate based flow cytometry and computational analysis for standardized immunological biomarker discovery. PLoS One (2013) 0.91
Integrative biology approach identifies cytokine targeting strategies for psoriasis. Sci Transl Med (2014) 0.89
Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology (2004) 0.88
Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity. PLoS One (2012) 0.87
Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics (2012) 0.87
An in-depth characterization of the major psoriasis susceptibility locus identifies candidate susceptibility alleles within an HLA-C enhancer element. PLoS One (2013) 0.86
Harnessing dendritic cells in inflammatory skin diseases. Semin Immunol (2011) 0.86
IgG4 antibodies and cancer-associated inflammation: Insights into a novel mechanism of immune escape. Oncoimmunology (2013) 0.83
Allele-specific cytokine responses at the HLA-C locus: implications for psoriasis. J Invest Dermatol (2011) 0.83
Animal models of psoriasis and psoriatic arthritis: an update. Curr Rheumatol Rep (2006) 0.80
Toward prediction of immune mechanisms and design of immunotherapies in melanoma. Crit Rev Biomed Eng (2012) 0.79
Advances in the treatment of melanoma. Clin Med (2012) 0.77
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol (2007) 0.77
What on "irf" is this gene 4? Irf4 transcription-factor-dependent dendritic cells are required for T helper 2 cell responses in murine skin. Immunity (2013) 0.75
A new lease on life for dendritic cell vaccines? Nat Biotechnol (2006) 0.75
Dendritic cell-based cancer therapy. Curr Opin Mol Ther (2003) 0.75
Painless erythema of the hands associated with non-Hodgkin's lymphoma in a lung transplant recipient. J Am Acad Dermatol (2002) 0.75
Antigen specific immunotherapy: Quo vadis? Swiss Med Wkly (2005) 0.75
Pathogenesis and immunotherapy in cutaneous psoriasis: what can rheumatologists learn? Curr Opin Rheumatol (2017) 0.75
Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors. Lung Cancer (2002) 0.75
Real-time polymerase chain reaction monitoring of epithelial cell adhesion molecule-induced T-cell stimulation in patients with lung cancer and healthy individuals using LightCycler technology. J Immunother (2002) 0.75
From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas. Recent Results Cancer Res (2002) 0.75